How and when to decide between epigenetic therapy and chemotherapy in patients with AML

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):45-53. doi: 10.1182/asheducation-2017.1.45.

Abstract

Remission induction with chemotherapy has long been the frontline treatment of acute myeloid leukemia (AML). However, intensive therapy is limited in frail patients by its associated toxicity and higher rates of failure or relapse in patients with chemoresistant disease, such as secondary AML or poor-risk cytogenetics. Frailty and chemoresistance are more frequent in older adults with AML. In recent years, epigenetic therapies with the hypomethylating agents decitabine and azacitidine have been thoroughly explored in AML. The results of two pivotal studies carried out with these agents in older adults with newly diagnosed AML have challenged the role of intensive chemotherapy as the frontline treatment option in this high-risk population. Here, we review the results of treatment with intensive chemotherapy and hypomethylating agents in older patients with AML; discuss the patient- and disease-specific criteria to integrate into treatment decision making; and also, highlight the methodological limitations of cross-study comparison in this population.

Publication types

  • Review

MeSH terms

  • Azacitidine / analogs & derivatives*
  • Azacitidine / therapeutic use*
  • Chromosome Aberrations*
  • Decision Making*
  • Decitabine
  • Epigenesis, Genetic*
  • Humans
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics

Substances

  • Decitabine
  • Azacitidine